Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

• Published in: Blood 2011-05, Vol.117 (18), p.4836-4843
• Main Authors: Gutiérrez-García, Gonzalo, Cardesa-Salzmann, Teresa, Climent, Fina, González-Barca, Eva, Mercadal, Santiago, Mate, José L., Sancho, Juan M., Arenillas, Leonor, Serrano, Sergi, Escoda, Lourdes, Martínez, Salomé, Valera, Alexandra, Martínez, Antonio, Jares, Pedro, Pinyol, Magdalena, García-Herrera, Adriana, Martínez-Trillos, Alejandra, Giné, Eva, Villamor, Neus, Campo, Elías, Colomo, Luis, López-Guillermo, Armando
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Disease-Free Survival; Female; Gene Expression Profiling; Hematologic and hematopoietic diseases; Humans; Immunohistochemistry; Immunophenotyping; Immunotherapy; Kaplan-Meier Estimate; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - immunology; Lymphoma, Large B-Cell, Diffuse - therapy; Male; Medical sciences; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Rituximab; Young Adult
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2010-12-322362

Diffuse large B-cell lymphomas (DLBCLs) can be divided into germinal-center B cell–like (GCB) and activated-B cell–like (ABC) subtypes by gene-expression profiling (GEP), with the latter showing a poorer outcome. Although this classification can be mimicked by different immunostaining algorithms, their reliability is the object of controversy. We constructed tissue microarrays with samples of 157 DLBCL patients homogeneously treated with immunochemotherapy to apply the following algorithms: Colomo (MUM1/IRF4, CD10, and BCL6 antigens), Hans (CD10, BCL6, and MUM1/IRF4), Muris (CD10 and MUM1/IRF4 plus BCL2), Choi (GCET1, MUM1/IRF4, CD10, FOXP1, and BCL6), and Tally (CD10, GCET1, MUM1/IRF4, FOXP1, and LMO2). GEP information was available in 62 cases. The proportion of misclassified cases by immunohistochemistry compared with GEP was higher when defining the GCB subset: 41%, 48%, 30%, 60%, and 40% for Colomo, Hans, Muris, Choi, and Tally, respectively. Whereas the GEP groups showed significantly different 5-year progression-free survival (76% vs 31% for GCB and activated DLBCL) and overall survival (80% vs 45%), none of the immunostaining algorithms was able to retain the prognostic impact of the groups (GCB vs non-GCB). In conclusion, stratification based on immunostaining algorithms should be used with caution in guiding therapy, even in clinical trials.